DALLAS & DUBLIN–(BUSINESS WIRE)–Nanoscope Therapeutics, Inc. (“Nanoscope”), a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has entered into an agreement with Uniphar, a global healthcare services partner to the pharmaceutical, biotech and medtech industries, under which Uniphar will serve as Nanoscope’s exclusive named patient s

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.